Impact of immunosuppressive drugs on the development of cardiac allograft vasculopathy.

Abstract:

:Immunosuppressive drugs (ISDs) have a major impact on the development and progression of cardiac allograft vasculopathy (CAV), the main cause of cardiac allograft loss and a leading cause of death beyond the 1st post-transplant year. The influence of ISDs on the development and progression of CAV is complex. In spite of their high potency to suppress the alloimmune response (prevention of allograft rejection) which plays an essential role in the pathogenesis of CAV, the immunosuppressive regimens which were used in the past were not able to entirely prevent the development of CAV. This can be explained by the fact that several non-alloimmune insults such as brain death, organ preservation, surgical trauma, ischemia-reperfusion, diabetes, hypertension, hyperlipidemia, cytomegalovirus infection etc. are also involved in the development or progression of CAV. Some of these insults are not affected by immunosuppression, whereas others can be even aggravated by certain ISDs, particularly by calcineurin inhibitors (CNIs), but also by glucocorticosteroids and proliferation signal inhibitors (PSIs). Certain ISDs, especially CNIs, also have direct toxic effects on vascular endothelial and smooth muscle cells inducing endothelial dysfunction and proliferation of both smooth muscle cells and fibroblasts which promotes the development and progression of CAV. Other ISDs like PSIs and mycophenolate mofetil appeared able to delay the onset of CAV and reduce its progression, especially by their inhibitory effects on smooth muscle cell migration and proliferation. The present article reviews the data available on the impact of different ISDs and regimens on the development and progression of CAV.

journal_name

Curr Vasc Pharmacol

authors

Dandel M,Hetzer R

doi

10.2174/157016110792006923

subject

Has Abstract

pub_date

2010-09-01 00:00:00

pages

706-19

issue

5

eissn

1570-1611

issn

1875-6212

pii

BSP/CVP/E-Pub/0000101

journal_volume

8

pub_type

杂志文章,评审
  • New Insights into the Role of FGF-23 and Klotho in Cardiovascular Disease in Chronic Kidney Disease Patients.

    abstract::Alterations of fibroblast growth factor 23 (FGF-23) and Klotho levels are considered to be the earliest biochemical abnormality of chronic kidney disease - mineral and bone disease (CKDMBD) syndrome. Moreover, emerging data suggests that the dysregulated FGF-23 and Klotho axis has many effects on the cardiovascular (C...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161118666200420102100

    authors: Memmos E,Papagianni A

    更新日期:2021-01-01 00:00:00

  • Statins May Prevent Atherosclerotic Disease in OSA Patients without Co-Morbidities?

    abstract::Obstructive sleep apnoea (OSA) is characterized by repetitive interruptions of breathing, causing Chronic Intermittent Hypoxia (CIH) that can be involved in the development and progression of cardiovascular diseases. There is evidence showing a close relationship between OSA and atherosclerosis, even in patients who d...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161114666161007164112

    authors: Toraldo DM,Benedetto M,Conte L,De Nuccio F

    更新日期:2017-01-01 00:00:00

  • Could Antioxidant Supplementation Delay Progression of Cardiovascular Disease in End-Stage Renal Disease Patients?

    abstract::In end-stage renal disease patients, the leading causes of mortality are of cardiovascular (CV) origin. The underlying mechanisms are complex, given that sudden heart failure is more common than acute myocardial infarction. A contributing role of oxidative stress is postulated, which is increased even at early stages ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161118666200317151553

    authors: Roumeliotis S,Roumeliotis A,Gorny X,Mertens PR

    更新日期:2021-01-01 00:00:00

  • Angiotensin 1-7 promotes cardiac angiogenesis following infarction.

    abstract::Angiogenesis is central to cardiac repair following myocardial infarction (MI). Cardiac angiotensin converting enzyme (ACE)2 significantly increased postMI, which is coincident with activated angiogenesis. The function of ACE2 is to generate angiotensin (Ang)1-7, an active peptide with cellular actions mediated by Mas...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/15701611113119990006

    authors: Zhao W,Zhao T,Chen Y,Sun Y

    更新日期:2015-01-01 00:00:00

  • What is the Role for Glycoprotein IIb/IIIa Inhibitor Use in the Catheterization Laboratory in the Current Era?

    abstract:BACKGROUND:In the era of dual antiplatelet therapy of aspirin and clopidogrel and systematic stent implantation, Glycoprotein IIb/IIIa Inhibitors (GPI), including abciximab, eptifibatide and tirofiban, proved beneficial in improving early outcome of Percutaneous Coronary Intervention (PCI), especially in higher risk cl...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161116666180117102422

    authors: Rubboli A,Patti G

    更新日期:2018-01-01 00:00:00

  • Effects of statins on blood pressure: a review of the experimental and clinical evidence.

    abstract::The "pleiotropic" effects of statins have been the centre of a considerable research activity. Among the numerous experimental and clinical studies of this field, some focused on the effects of statins on blood pressure (BP), while others reported data on BP together with other parameters. Some of the animal or human ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016107780368307

    authors: Sarafidis PA,Kanaki AI,Lasaridis AN

    更新日期:2007-04-01 00:00:00

  • Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment.

    abstract:AIM:To assess the potential differences in the metabolic and cardiovascular disease (CVD) risk between the distinct phenotypes of the Polycystic Ovary Syndrome (PCOS) according to the Rotterdam definition regardless of body mass index (BMI). PATIENTS-METHODS:The study included 300 women; 240 women with PCOS, according...

    journal_title:Current vascular pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.2174/1567201812666150120163025

    authors: Daskalopoulos G,Karkanaki A,Piouka A,Prapas N,Panidis D,Gkeleris P,Athyros VG

    更新日期:2015-01-01 00:00:00

  • Functional link between adenosine and insulin: a hypothesis for fetoplacental vascular endothelial dysfunction in gestational diabetes.

    abstract::Gestational diabetes mellitus (GDM) is a syndrome compromising the health of the mother and the fetus. Endothelial damage and reduced metabolism of the vasodilator adenosine occur and fetal hyperinsulinemia associated with deficient insulin response and a metabolic rather than mitogenic phenotype is characteristic of ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111797484062

    authors: Guzmán-Gutiérrez E,Abarzúa F,Belmar C,Nien JK,Ramírez MA,Arroyo P,Salomón C,Westermeier F,Puebla C,Leiva A,Casanello P,Sobrevia L

    更新日期:2011-11-01 00:00:00

  • Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists.

    abstract::Several lines of evidence suggest a detrimental effect of aldosterone excess on the development of metabolic alterations. Glucose metabolism derangements due to aldosterone action are frequently observed not only in patients with primary aldosteronism but also in patients with obesity. A contribution to the hyperaldos...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016112799304969

    authors: Ronconi V,Turchi F,Appolloni G,di Tizio V,Boscaro M,Giacchetti G

    更新日期:2012-03-01 00:00:00

  • Nitric Oxide is a Central Common Metabolite in Vascular Dysfunction Associated with Diseases of Human Pregnancy.

    abstract::Preeclampsia (PE), gestational diabetes mellitus (GDM), and maternal supraphysiological hypercholesterolaemia (MSPH) are pregnancy-related conditions that cause metabolic disruptions leading to alterations of the mother, fetus and neonate health. These syndromes result in fetoplacental vascular dysfunction, where nitr...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161114666160222115158

    authors: Leiva A,Fuenzalida B,Barros E,Sobrevia B,Salsoso R,Sáez T,Villalobos R,Silva L,Chiarello I,Toledo F,Gutiérrez J,Sanhueza C,Pardo F,Sobrevia L

    更新日期:2016-01-01 00:00:00

  • Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency.

    abstract::Initially, the progression of chronic venous insufficiency is related to venous hypertension. The earliest complaints or symptoms, as well as vessel wall deterioration, valve restructuring, and, eventually, varicose veins, result not only from elevation of pressure, but also from a cascade of biochemical events relate...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161052773870

    authors: Katsenis K

    更新日期:2005-01-01 00:00:00

  • Pleiotropic effects of the rho-kinase inhibitor fasudil after subarachnoid hemorrhage: a review of preclinical and clinical studies.

    abstract::There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161112666140613115813

    authors: Satoh S,Ikegaki I,Kawasaki K,Asano T,Shibuya M

    更新日期:2014-01-01 00:00:00

  • Atherogenesis in renal patients: a model of vascular disease?

    abstract::Chronic kidney disease (CKD), and particularly kidney failure, is associated with accelerated atherosclerosis and approximately a 20-fold increased risk of cardiovascular death. The majority of these patients die from complications directly attributed to atherosclerosis and their life expectancy is decreased. Establis...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016108783955374

    authors: Efstratiadis G,Tziomalos K,Mikhailidis DP,Athyros VG,Hatzitolios A

    更新日期:2008-04-01 00:00:00

  • Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial.

    abstract:OBJECTIVE:To reveal the cutoff point and influencing factors in the dynamic change in phenotypic group in patients with stable angina pectoris (SAP) after Xinxuekang capsule treatment. METHODS:Five hundred and seventy-six SAP patients were randomly assigned to receive Xinxuekang (XXK) capsules or Compound Danshen (CDS...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2174/1570161112666141014151858

    authors: Wang LY,Tang JY,Liu J,Lu W,Yu YN,Chen BW,Wu HL,Su LY,Jing ZW,Hu SY,Liu XL,Yang XY,Li GX,Dong B,Wang DH,Xue J,Wang XF,Li ZM,Liu SR,Liu SS,Chen QG,Zhang L,Wang Z,Shen CT,Wang YY

    更新日期:2015-01-01 00:00:00

  • Pleiotropic effects of ARB in vascular metabolism--focusing on atherosclerosis-based cardiovascular disease.

    abstract::The renin-angiotensin system (RAS) plays an essential role in fluid and electrolyte homeostasis and the regulation of vascular tone; however, dysregulation and over-activation of the RAS lead to the pathogenesis of various cardiovascular diseases. The RAS is closely associated with NADPH oxidase, a major enzymatic sou...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111794519273

    authors: Honjo T,Yamaoka-Tojo M,Inoue N

    更新日期:2011-03-01 00:00:00

  • The role of nitric oxide on endothelial function.

    abstract::The vascular endothelium is a monolayer of cells between the vessel lumen and the vascular smooth muscle cells. Nitric oxide (NO) is a soluble gas continuously synthesized from the amino acid L-arginine in endothelial cells by the constitutive calcium-calmodulin-dependent enzyme nitric oxide synthase (NOS). This subst...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016112798829760

    authors: Tousoulis D,Kampoli AM,Tentolouris C,Papageorgiou N,Stefanadis C

    更新日期:2012-01-01 00:00:00

  • New Insight into the Mechanisms of Ginkgo Biloba Extract in Vascular Aging Prevention.

    abstract:BACKGROUND:Aging-associated vascular dysfunction promotes cardiovascular diseases. Recently, Ginkgo biloba extract (GBE) has attracted considerable attention in the prevention of aged vasculature. METHODS:This review discusses the pathophysiological alterations in aged vasculature and the underlying mechanisms of GBE ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161117666190621150725

    authors: Li X,Lu L,Chen J,Zhang C,Chen H,Huang H

    更新日期:2020-01-01 00:00:00

  • Thromboembolic complications in malignant haematological disorders.

    abstract::It is well known that solid cancers are associated with thromboembolic complications, but recent studies have shown that the incidence of thrombosis may be as high (or even higher) in patients with malignant haematological disorders. However, this may be obscured by the significant morbidity and mortality due to other...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110791330799

    authors: Castelli R,Ferrari B,Cortelezzi A,Guariglia A

    更新日期:2010-07-01 00:00:00

  • Clinical implications of non-invasive measurement of central aortic blood pressure.

    abstract::Central arterial systolic blood pressure is a very important factor in the pathophysiology of cardiovascular diseases. Central arterial pressure is a better predictor of cardiovascular risk than peripheral brachial blood pressure. Measurement of central blood pressure is useful for a diagnosis of spurious systolic hyp...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110793563852

    authors: Stepień M,Banach M,Jankowski P,Rysz J

    更新日期:2010-11-01 00:00:00

  • Clinical management of the cardiovascular failure in sepsis.

    abstract::Cardiovascular failure in sepsis involves a combination of hypovolemia, decreased vascular tone, myocardial depression and microcirculatory alterations. Fluids represent the first line therapeutic intervention, with controversy regarding the type of fluid. Recent data indicate that albumin is safe and might even be be...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: De Backer D,Scolletta S

    更新日期:2013-03-01 00:00:00

  • Vitamin D is Related to Markers of Vulnerable Plaque in Acute Myocardial Infarction.

    abstract:BACKGROUND:Vitamin D is a fat soluble vitamin involved in calcium and bone metabolism; recently its deficiency has been related to cardiovascular disease. In cardiac tissue, vitamin D suppresses metalloproteinases (MMPs) expression, enzymes directly associated with vulnerable plaque. OBJECTIVE:To investigate whether t...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161115666170609102506

    authors: Machulsky NF,Barchuk M,Gagliardi J,Gonzalez D,Lombardo M,Escudero AG,Gigena G,Blanco F,Schreier L,Fabre B,Berg G

    更新日期:2018-01-01 00:00:00

  • Paraoxonase-1: Characteristics and Role in Atherosclerosis and Carotid Artery Disease.

    abstract::Paraoxonase-1 (PON-1) is a calcium-dependent enzyme that is synthesized in the liver and then secreted in blood where it is bound to high density lipoprotein (HDL). PON-1 is a hydrolase with a wide range of substrates, including lipid peroxides. It is considered responsible for many of the antiatherogenic properties o...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161115666171129212359

    authors: Lioudaki S,Verikokos C,Kouraklis G,Ioannou C,Chatziioannou E,Perrea D,Klonaris C

    更新日期:2019-01-01 00:00:00

  • Involvement of coagulation and hemostasis in inflammatory bowel diseases.

    abstract::Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) are idiopathic, intestinal and systemic inflammatory disorders which are immunologically mediated with the activation of plasma proteolytic cascades. The activation of coagulation in IBD is related to the activity and colonic extension of t...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016112801784495

    authors: Stadnicki A

    更新日期:2012-09-01 00:00:00

  • Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases.

    abstract::In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis fac...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161052773898

    authors: Kułdo JM,Ogawara KI,Werner N,Asgeirsdóttir SA,Kamps JA,Kok RJ,Molema G

    更新日期:2005-01-01 00:00:00

  • Hypertension: quo vadis?

    abstract::High blood pressure (BP) along with smoking habit and lipid disorders are the most important and modifiable risk factors for cardiovascular diseases. However, the prevalence of high BP has grown progressively over time with a progressive increase not only in the absolute number of patients but in the proportion of tho...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016112803520927

    authors: Borghi C

    更新日期:2012-11-01 00:00:00

  • Heart Failure Models: Traditional and Novel Therapy.

    abstract::Cardiovascular disease (CVD) is among the most major causes of morbidity and mortality worldwide. Great progress has been made in the management of CVD which has been influenced by the use of experimental animal models. These models provided information at cellular and molecular levels and allowed the development of t...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161113666150212151506

    authors: Haidara MA,Assiri AS,Yassin HZ,Ammar HI,Obradovic MM,Isenovic ER

    更新日期:2015-01-01 00:00:00

  • Renalase is removed by kidneys and during dialysis - excess related to CKD complications?

    abstract:BACKGROUND:The most common complications of chronic kidney disease (CKD) are hypertension and cardiovascular (CV) disorders. Renalase is produced and released by the kidney and also cardiomyocytes. Renalase deficiency was claimed to be responsible for hypertension and CV complication in CKD. There are contradictory dat...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161113666141217141805

    authors: Malyszko J,Koc-Zorawska E,Zorawski M,Kozminski P,Zbroch E,Rysz J,Banach M,Malyszko JS

    更新日期:2015-01-01 00:00:00

  • Prevalence, diagnosis and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?

    abstract:BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH), are major health problems worldwide. Genetics may play a role in the pathogenesis of NAFLD/NASH. AIM:To investigate the prevalence of NAFLD/NASH in 5,400 military personnel and evaluate the effect of treatme...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161118666201015152921

    authors: Sfikas G,Psallas M,Koumaras C,Imprialos K,Perdikakis E,Doumas M,Giouleme O,Karagiannis A,Athyros VG

    更新日期:2020-10-15 00:00:00

  • Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.

    abstract:BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the general population. The disease ranges from simple steatosis, to non-alcoholic steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma. Several drugs are used in daily clinical practice to manage the disease. However, dat...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161115666170621083744

    authors: Imprialos K,Stavropoulos K,Bouloukou S,Kerpiniotis G,Karagiannis A,Doumas M

    更新日期:2018-01-01 00:00:00

  • Endothelial dysfunction in cardiac allograft vasculopathy: potential pharmacological interventions.

    abstract::Nowadays long-term outcome of heart transplantation is limited by a peculiar type of coronary atherosclerosis, known as cardiac allograft vasculopathy (CAV). Although the exact pathogenesis of CAV remains unclear, emerging evidence indicates that the endothelium plays a significant role in the onset and progression of...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110790886992

    authors: Osto E,Tona F,De Bon E,Iliceto S,Cella G

    更新日期:2010-03-01 00:00:00